Comparison of @entity859 effects on atrioventricular node reentry and XXXX .

@entity1 @entity2917 @entity859 @entity591 @entity16992 @entity3044 @entity4710
BACKGROUND: @entity859 is an established first line therapy for the treatment of narrow @entity591 . The two most common etiologies of paroxysmal @entity4710 ( @entity4710 ) are @entity2917 ( @entity2917 ) and @entity16992 ( @entity16992 ). HYPOTHESIS: We postulated that @entity859 might have different effects on the termination of @entity2917 vs. @entity16992 , and that these differences might assist in the noninvasive differentiation between these diagnoses. METHODS: Fifty-nine @entity1 referred for the diagnosis and treatment of @entity4710 were included in the study. All @entity1 had @entity4710 induced during electrophysiology testing, and each @entity1 received @entity859 during @entity4710 . The @entity859 dose, time to @entity591 termination, and site of @entity591 termination were recorded. Seventeen @entity1 required @entity3044 administration to initiate @entity4710 . This subset of @entity1 was compared with those not requiring @entity3044 . RESULTS: There was no statistically significant difference in the @entity859 dose or time to @entity591 termination when comparing @entity1 with @entity2917 with those with @entity16992 . All @entity1 with @entity2917 had termination of @entity591 in the antegrade direction with final activation in the atria. @entity1 requiring @entity3044 for @entity591 initiation experienced @entity591 termination significantly faster than those not requiring @entity3044 , although there was no difference in the dose of @entity859 required for termination. CONCLUSION: These data demonstrate that @entity1 with dual AV node physiology and @entity2917 do not have altered sensitivity to @entity859 compared with @entity1 with @entity16992 and normal AV nodes. Further investigation will be required to determine the clinical utility of the significantly shorter time to @entity591 termination for @entity1 receiving @entity3044 .
